The authors analyzed baseline plasma samples from 310 treated patients (148 INF; 162 BEV+INF) using an optimized multiplex ELISA platform for HGF at baseline and after 4 weeks on treatment. Primary endpoint was OS.
The results demonstrated that the median baseline HGF level in all 310 pts was 161.4 pg/ml. Elevated HGF at 4-wks (>median) was associated with a worse OS (median OS = 14 vs 27 months; adjusted hazard ratio (HR) = 1.75, p< 0.0001). Only 9/155 pts (5.8%) with baseline HGF levels ≤ median developed elevated HGF (>median) at 4-wks. Additionally, 66/155 pts (43%) with baseline HGF levels >median lowered HGF (<median) at 4-wks from baseline. A decline in HGF levels at 4-wks (< median) was associated with improved OS when compared to patients with high HGF (19 vs 13 months, adjusted HR=1.41, p=0.043).
In conclusion, RCC pts with low baseline HGF levels (< median), continue to have consistently low levels at 4 weeks’ time, which are associated with improved OS. Conversely, in patients with high baseline HGF levels final outcome can vary; with patients demonstrated to have high levels on treatment, eventually also having a worse OS, while those having lower levels during treatment, having a better OS. This suggests that low HGF predicts a therapeutic benefit and warrants further research.
Presented By: Daniel J. George, Duke Cancer Institute, Duke University Medical Center, Durham, NC
Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre
at the 2017 ASCO Annual Meeting - June 2 - 6, 2017 – Chicago, Illinois, USA